2016
A CONVERSATION WITH VINCENT DEVITA, MD. No Truce Sought in Cancer War: 'We Want to Cure This Disease'.
DeVita V, Wehrwein P. A CONVERSATION WITH VINCENT DEVITA, MD. No Truce Sought in Cancer War: 'We Want to Cure This Disease'. Managed Care 2016, 25: 39-41. PMID: 26882628.Peer-Reviewed Original ResearchAntineoplastic AgentsDisease EradicationDrug IndustryNeoplasmsUnited StatesUnited States Food and Drug Administration
2009
Off-label use of approved drugs
DeVita V. Off-label use of approved drugs. Nature Reviews Clinical Oncology 2009, 6: 181-181. PMID: 19333219, DOI: 10.1038/nrclinonc.2009.41.Peer-Reviewed Original Research
2007
The Provenge® decision
DeVita V. The Provenge® decision. Nature Reviews Clinical Oncology 2007, 4: 381-381. PMID: 17554239, DOI: 10.1038/ncponc0854.Peer-Reviewed Original ResearchAdvisory CommitteesCancer VaccinesClinical Trials as TopicDrug ApprovalHumansMaleProstatic NeoplasmsTissue ExtractsUnited StatesUnited States Food and Drug Administration
2006
A step in the right direction
DeVita V. A step in the right direction. Nature Reviews Clinical Oncology 2006, 3: 641-641. PMID: 17139311, DOI: 10.1038/ncponc0669.Peer-Reviewed Original ResearchAntimetabolites, AntineoplasticDeoxycytidineDrug ApprovalEndpoint DeterminationFemaleGemcitabineHumansNeoplasmsOvarian NeoplasmsSurvival AnalysisUnited StatesUnited States Food and Drug Administration
2005
Should the FDA be the doctor of last resort?
DeVita V. Should the FDA be the doctor of last resort? Nature Reviews Clinical Oncology 2005, 2: 423-423. PMID: 16264991, DOI: 10.1038/ncponc0292.Peer-Reviewed Original ResearchAntineoplastic AgentsClinical Trials as TopicDecision MakingDrug ApprovalHumansMedical OncologyResearch DesignUnited StatesUnited States Food and Drug Administration